Abhishek Singla , MD

Doctor of Medicine : Maulana Azad Medical College, University of Delhi New Delhi, India, 2010 (Internal Medicine)

MBBS: University College of Medical Sciences, University of Delhi, New Delhi, India, 2005 (Bachelor of Medicine and Bachelor of Surgery (MBBS),)

Residency: Creighton University Medical Center, Omaha, NE, 2014 (Internal Medicine Residency )

Fellowship: University of Cincinnati Medical Center Cincinnati, Ohio, 2017 (Pulmonary and Critical Care)

Masters in Clinical & Translational Research: University of Cincinnati Cincinnati, OH, 2019

American Board of Internal Medicine (Critical Care Medicine) (Certification Date: 10-18-2017 )

American Board of Internal Medicine (Certification Date: 08-13-2014 )

American Board of Internal Medicine (Pulmonary Disease) (Certification Date: 10-05-2016 )

Critical Care Medicine

Lung Disease

Pulmonary Disease

Rare Lung Disease

Sarcoidosis

Asbestosis

Bronchiolitis

Chronic Cough

Dyspnea

Histoplasmosis

Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease (ILD)

Legionnaires' Disease (Legionellosis)

Pleurisy

Pneumonia

Pneumonitis

Pulmonary Fibrosis

Pulmonary Sarcoidosis

Respiration Disorders

Respiratory Syncytial Virus (RSV)

Respiratory Tract Disease

Respiratory Tract Infections

Shortness of Breath

Thoracic Cancer

Tuberculosis

Whooping Cough (Pertussis)

Pulmonary Embolism

Pulmonary Hypertension

Critical Care Medicine

Internal Medicine

Pulmonary and Critical Care

Grant: #KIN-1902-2001 Investigators:Singla, Abhishek 06-01-2022 -05-31-2025 Kinevant Sciences, GmbH A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis. Role:PI 322299.85 Hold Level:Industry

Grant: #LYT-100-2022-204 Investigators:Singla, Abhishek 03-07-2023 -03-06-2026 PureTech LYT 100, Inc. A RANDOMIZED, DOUBLE-BLIND, FOUR-ARM ACTIVE AND PLACEBO-CONTROLLED DOSE FINDING TRIAL TO EVALUATE THE EFFICACY, TOLERABILITY AND SAFETY DOSE RESPONSE OF LYT-100 IN PATIENTS WITH IDIOPATHIC PULMONA Role:PI 0.00 Hold Level:Industry

Grant: #PLN74809-000 Investigators:Singla, Abhishek 01-29-2024 -01-28-2027 Pliant Therapeutics, Inc. A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON) Role:PI 136993.23 Active Level:Industry

Peer Reviewed Publications

Singla A.; Kopras E.J.; Gupta N. (11-01-2019. ) Spontaneous pneumothorax and air travel in Pulmonary Langerhans cell histiocytosis: A patient survey.Respiratory Investigation, , 57 (6 ) ,582-589 More Information

Singla A.; Gupta N.; Apewokin S.; McCormack F. (11-02-2017. ) Sirolimus for the treatment of lymphangioleiomyomatosis.Expert Opinion on Orphan Drugs, , 5 (11 ) ,907-921 More Information